Christopher T. Gubish

1.9k total citations
17 papers, 1.6k citations indexed

About

Christopher T. Gubish is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Christopher T. Gubish has authored 17 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Hepatology. Recurrent topics in Christopher T. Gubish's work include Liver physiology and pathology (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Christopher T. Gubish is often cited by papers focused on Liver physiology and pathology (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Christopher T. Gubish collaborates with scholars based in United States, China and Hong Kong. Christopher T. Gubish's co-authors include Jill M. Siegfried, Laura P. Stabile, Jennifer R. Grandis, James D. Luketich, Sydney Finkelstein, Neil A. Christie, Weiping Zhang, Sharon P. Shriver, Mary E. Rothstein and Sufi M. Thomas and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and Oncogene.

In The Last Decade

Christopher T. Gubish

16 papers receiving 1.6k citations

Peers

Countries citing papers authored by Christopher T. Gubish

Since Specialization

Citations

This map shows the geographic impact of Christopher T. Gubish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher T. Gubish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher T. Gubish more than expected).

Fields of papers citing papers by Christopher T. Gubish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher T. Gubish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher T. Gubish. The network helps show where Christopher T. Gubish may publish in the future.

Co-authorship network of co-authors of Christopher T. Gubish

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher T. Gubish. A scholar is included among the top collaborators of Christopher T. Gubish based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher T. Gubish. Christopher T. Gubish is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF 2014 ·Journal of Thoracic Oncology ·Laura P. Stabile, Mary E. Rothstein, Christopher T. Gubish, Diana E. Cunningham, Nathan Lee, Jill M. Siegfried	7
2	Abstract 2026: Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened HGF signaling in the airways. 2013 ·Cancer Research ·Laura P. Stabile, Mary E. Rothstein, Christopher T. Gubish, Nathan Lee, Diana E. Cunningham, Jill M. Siegfried	0
3	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met 2012 ·Clinical Cancer Research ·Laura P. Stabile, (unknown), Vivian Wai Yan Lui, Sufi M. Thomas, Cassandra L. Henry, Christopher T. Gubish, Sonali Joyce, Kelly M. Quesnelle, Jill M. Siegfried, Jennifer R. Grandis	81
4	Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer 2012 ·Journal of Thoracic Oncology ·Jill M. Siegfried, Christopher T. Gubish, Mary E. Rothstein, Cassandra L. Henry, Laura P. Stabile	47
5	Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells 2011 ·Clinical Cancer Research ·(unknown), Laura P. Stabile, Christopher T. Gubish, William E. Gooding, Jennifer R. Grandis, Jill M. Siegfried	97
6	HGF-independent potentiation of EGFR action by c-Met 2011 ·Oncogene ·Austin Dulak, Christopher T. Gubish, Laura P. Stabile, (unknown), Jill M. Siegfried	94
7	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer 2009 ·Clinical Cancer Research ·Lynn M. Knowles, Laura P. Stabile, Ann Marie Egloff, Mary E. Rothstein, Sufi M. Thomas, Christopher T. Gubish, Edwina C. Lerner, Raja R. Seethala, Shinsuke Suzuki, Kelly M. Quesnelle, Sarah Morgan, Robert L. Ferris, Jennifer R. Grandis, Jill M. Siegfried	175
8	Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non–Small-Cell Lung Cancer 2007 ·Molecular Pharmacology ·Jill M. Siegfried, Christopher T. Gubish, Mary E. Rothstein, (unknown), Laura P. Stabile	35
9	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer 2007 ·Molecular Cancer Therapeutics ·Qing Zhang, Neil E. Bhola, Vivian Wai Yan Lui, Doris R. Siwak, Sufi M. Thomas, Christopher T. Gubish, Jill M. Siegfried, Gordon B. Mills, Dong M. Shin, Jennifer R. Grandis	68
10	Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects 2005 ·Cancer Research ·Laura P. Stabile, (unknown), Christopher T. Gubish, Weiping Zhang, Jennifer R. Grandis, Jill M. Siegfried	263
11	The HER2 tyrosine kinase is a direct target of erlotinib (Tarceva™), a potent inhibitor of EGFR/HER1 kinase. 2004 ·Cancer Research ·Laura P. Stabile, (unknown), Christopher T. Gubish, Jill M. Siegfried	2
12	Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. 2002 ·PubMed ·Laura P. Stabile, (unknown), Christopher T. Gubish, (unknown), James D. Luketich, Neil A. Christie, Sydney Finkelstein, Jill M. Siegfried	394
13	Sex-Specific Expression of Gastrin-Releasing Peptide Receptor: Relationship to Smoking History and Risk of Lung Cancer 2000 ·JNCI Journal of the National Cancer Institute ·Sharon P. Shriver, (unknown), Christopher T. Gubish, (unknown), Alan L. Davis, James D. Luketich, Jill M. Siegfried	153
14	Evidence for Autocrine Actions of Neuromedin B and Gastrin-releasing Peptide in Non-small Cell Lung Cancer 1999 ·Pulmonary Pharmacology & Therapeutics ·Jill M. Siegfried, Krishnamachary Nandigama, (unknown), Christopher T. Gubish, Jay D. Hunt, Sharon P. Shriver	86
15	The clinical significance of hepatocyte growth factor for non–small cell lung cancer 1998 ·The Annals of Thoracic Surgery ·Jill M. Siegfried, Lisa A. Weissfeld, James D. Luketich, Robert J. Weyant, Christopher T. Gubish, Rodney J. Landreneau	78
16	Activity of anti-erbB-2 recombinant toxin OLX-209 on lung cancer cell lines in the absence of erbB-2 gene amplification 1996 ·Lung Cancer ·Philip G. Kasprzyk, (unknown), Jay D. Hunt, Christopher T. Gubish, (unknown), (unknown), Robert E. Bird, Paul Fischer, Jill M. Siegfried, C. Richter King	13
17	Zinc Nutritional Status Modulates the Response of 1,25-Dihydroxycholecalciferol to Calcium Depletion in Rats 1992 ·Journal of Nutrition ·Paul L. Kimmel, Christopher T. Gubish, (unknown), Craig B. Langman	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact